Brief: Hansa Biopharma Total Q2 Revenue Of SEK 36.7 Mln
20/07/2023 06:11
July 20 (Reuters) - Hansa Biopharma AB HNSA.ST :
* TOTAL Q2 REVENUE OF SEK 36.7M CONSISTING OF SEK 29.6M IN
PRODUCT
SALES AND SEK 7.1M IN REVENUE RECOGNITION
Source text for Eikon: ID:nWkrXdZbb
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS